Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Kv1.5 is a voltage-gated potassium channel encoded by the KCNA5 gene. It plays a crucial role in repolarizing atrial action potentials and is therefore a potential therapeutic target for atrial fibrillation. It also contributes to other physiological processes, including insulin secretion and pulmonary vascular tone. Mutations or dysfunction of Kv1.5 are associated with atrial fibrillation, sudden cardiac death, and pulmonary hypertension.
Channel blocker (Note: this requires more specific drug information to detail accurately)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Potassium voltage-gated channel subfamily A member 5 (Kv1.5).